Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance

Indivior Pharmaceuticals Inc. Common StockTrade
USA Rare Earth Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Indivior Pharmaceuticals Inc. Common Stock vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B), while USA Rare Earth Inc. Class A Common Stock trades at $10.13 (market cap $4.23B). The key difference: Indivior Pharmaceuticals Inc. Common Stock and USA Rare Earth Inc. Class A Common Stock are close in size by market cap, and Indivior Pharmaceuticals Inc. Common Stock is trading nearer its 52-week high, USA Rare Earth Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.

INDVUSAR
Market Cap
$4.18B$4.23B
Volume
1,819,74613,677,660
Sector
HealthBasic Materials
52-Week High
$41.83$33.68
52-Week Low
$24.09$10.32
Typical Hold Time
0 Days0 Days
Enterprise Value
$4.47B$2.70B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Indivior Pharmaceuticals Inc. Common Stock

No Aura AI signal available yet.

USA Rare Earth Inc. Class A Common Stock

USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.

The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INDV
100% Buy0% Sell
Avg holding period · 0 Days
USAR
100% Buy0% Sell
Avg holding period · 0 Days

About Indivior Pharmaceuticals Inc. Common Stock

Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.

Read more on INDV →

About USA Rare Earth Inc. Class A Common Stock

USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.

Read more on USAR →